Catalio’s portfolio includes many notable local biotech companies, including Personal Genome Diagnostics Inc. and Thrive Earlier Detection Corp.
Image: George Petrocheilos (right) and R. Jacob Vogelstein are the managing partners of venture investment fund Catalio Capital Management LP. MARK DENNIS – https://www.bizjournals.com
GAITHERSBURG, MD — October 6, 2020 – NexImmune, a clinical-stage biotechnology company developing a portfolio of unique non-genetically-engineered T cell immunotherapies, announced today that it has dosed the first patient in its Phase 1/2 clinical trial for NEXI-002. NEXI-002 is a patient-derived cellular product that contains populations of naturally-occurring CD8+ T cells directed against several multiple myeloma (MM)-specific antigen targets. It is the second clinical product NexImmune has generated with its AIM nanoparticle technology.
“While the primary objective in this trial with NEXI-002 is to demonstrate safety and tolerability, we also hope to see initial signs of immunological and clinical activity,” said Han Myint, MD, Chief Medical Officer at NexImmune. “The AIM technology gives us the unique ability to direct populations of natural T cells against a powerful combination of cell surface and endogenous anti-tumor targets specific to multiple myeloma. We believe this approach has potential to address primary tumor escape mechanisms, and provide deep and durable clinical responses.”
Maryland universities are home to lots of cyber researchers and technologists working on new ways to secure our increasingly technology-reliant society. Those higher education institutions are also home to graduate students looking for an entrepreneurial leap.
A new program is looking to connect the two, and form new startups in the process.
The Maryland New Venture Fellowship for Cybersecurity, created by University of Maryland, Baltimore County incubator bwtech@UMBC and the University System of Maryland, is launching this fall to support 10 early-stage teams. The program was recently awarded $594,000 in federal funds from the Economic Development Administration of the United States Department of Commerce. With matching funds from Baltimore County, the total funding reaches about $1.3 million.
Image: Welcome to bwtech@UMBC. – Courtesy Photo
Our allergy assets remain an underpinning of Immunomic Therapeutics’ success, and have enabled our pivot to focus on oncology.
In addition to our canine atopic dermatitis vaccine concept, our vaccines using ITI’s lysosomal targeting technology have already been tested in several clinical studies in both allergy and oncology.
IMN’s Virtual Investors’ Conference on BioHealth, taking place November 18, will provide a platform to understand the intersection of securitization across the biotech and healthcare sector, helping educate investors, borrowers and industry participants on the hottest new asset class in equity capital markets. This one-day virtual conference will focus on both on European and U.S. opportunities and challenges, as regulatory challenges will be forefront on both sides of the globe.
BioHealth issuance in 2020 has now surpassed $60 billion globally, spurring this asset class to become the second most popular equity capital markets sector, with momentum driven by huge secondary moves and companies benefitting from a greater focus on healthcare investing that Covid-19 has generated.
Join this must-attend gathering to engage with hedge funds, institutional investors, and more, to discover exciting new investment opportunities as this sector expands to comply with policy, market demand and changing consumer needs.
All the fundamentals are aligning for the life sciences industry, as Covid-19 accelerates already growing demand for real estate in the sector.
Rents are rising for lab space, vacancies are plunging and research and development, and employment and new development are expanding further, thanks to strong venture capital investment.
In the top life sciences markets there’s currently about 13.9 million square feet of space under construction, but active tenant demand is outpacing that, running at about 14.7 million square feet, according to a new report from CBRE. Lab-space vacancy is historically low at less than 8% percent in most top life sciences markets, pushing rents higher.
You are invited to continue strengthening the Québec-Maryland collaboration!
Objectives of this webinar
Introductory remarks
Québec Delegate General in New York, Catherine Loubier
Schedule
The importance of the life sciences sector for Québec and the State of Maryland
Minister of International Relations and La Francophonie, and
Minister of Immigration, Francization and Integration, Nadine Girault
Secretary of Commerce for the State of Maryland, Kelly Schulz
Québec-Maryland collaboration agreement in life sciences and public health
Montréal’s life sciences ecosystem
CEO of Montréal In Vivo, Frank Béraud
Québec City’s life sciences ecosystem
CEO of Québec International, Carl Viel
Maryland’s life sciences and public health ecosystem
Director of BioHealth and Life Sciences, Maryland Department of Commerce, Ulyana Desiderio
Q&A with the panelists
Register here
https://us02web.zoom.us/webinar/register/WN_ozdJpKpXSMC9n0Esrqo-rA
Montgomery County Economic Development Corporation (MCEDC) President and CEO Benjamin Wu Chats with Rich Bendis on BioTalk.
Listen now Apple https://apple.co/2SJB2a5, Google https://bit.ly/2SMLbmd, Spotify https://spoti.fi/34SWcrI, https://bit.ly/2SMde5j, and YouTube Audio https://bit.ly/2GSHXeu
As the President and Chief Executive Officer of MCEDC, Ben Wu leads the public-private economic development of Maryland’s largest jurisdiction which comprises 25% of the state’s economy with a GDP greater than 13 states. A Montgomery County native, Ben is an accomplished executive with over three decades of professional experience leading operations at the highest levels of our nation and state.
Join fellow biotech leaders and is presented by the Association of University Research Parks, AstraZeneca, BioHealth Innovation, Children’s National Health System, Emergent BioSolutions, George Mason University, J.P. Morgan, Johns Hopkins University, Maryland Department of Commerce, Virginia Bio, and Wilson Sonsini Goodrich & Rosati, P.C.
Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our 6th Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.
We are excited to bring you an exceptional line up of more than 55 BioHealth Capital Region industry leaders to this virtual event!
